R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Move amid evidence of widespread reporting gaps
AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Paves the way for next-gen ultra-precise gas sensing
A major push to sharpen the future of cancer treatment is underway
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
Scientists at the forum warned of an increasingly volatile health landscape
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
